/ 25 Shares
21-Nov-2025 - 25-Nov-2025
₹ 563 - ₹ 593
₹ 14825.00
25
15,092,750
Face Value - ₹ 1/- Per Share
Listing at BSE, NSE
211,298 Application Required in Retail for 1 Time.
Registrar : Link Intime India Private Ltd
| Category | % | Shares/Amount |
|---|---|---|
| QIB | 50% | 7,546,373 Shares RS.447.50 CR |
| HNI 1 | 5% | 754,638 Shares RS.44.75 CR @ 2156 FORM 1X |
| HNI 2 | 10% | 1,509,275 Shares RS.89.50 CR @ 4312 FORM 1X |
| Retail | 35% | 5,282,463 Shares RS.313.25 CR @ 211299 FORM 1X |
| Retail (Upto 2 Lakh) | HNI (2 Lakh to 10 Lakh) | HNI (Above 10 Lakh) |
|---|---|---|
| 211299 FORM 1X | 2156 FORM 1X | 4312 FORM 1X |
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Upto 2 Lakh) | 1 | 25 | ₹ 14,825 |
| Retail (Upto 2 Lakh) | 13 | 325 | ₹ 192,725 |
| S-HNI (2 Lakh to 10 Lakh) | 14 | 350 | ₹ 207,550 |
| S-HNI (2 Lakh to 10 Lakh) | 67 | 1675 | ₹ 993,275 |
| B-HNI (Above 10 Lakh) | 68 | 1700 | ₹ 1,008,100 |
21-Nov-2025 17:37
| Category | Book Size | Subscription | No. of Times |
|---|---|---|---|
| QIB | 3,018,550 ₹ 179.00 Cr. | 269,925 ₹ 16.01 Cr. | 0.09x |
| HNI (<10 LAKH) | 754,638 ₹ 44.75 Cr. | 2,656,075 ₹ 157.51 Cr. | 3.52x |
| HNI2 (>10 LAKH) | 1,509,275 ₹ 89.50 Cr. | 4,145,775 ₹ 245.84 Cr. | 2.75x |
| RETAIL | 5,282,463 ₹ 313.25 Cr. | 8,007,125 ₹ 474.82 Cr. | 1.52x |
| Total | 10,564,926 | 15,078,900 | 1.43x |
| Category | Book Size | Subscription | No. of Times |
|---|---|---|---|
| QIB | 3,018,550 ₹ 179.00 Cr. | 269,925 ₹ 16.01 Cr. | 0.09x |
| HNI (<10 LAKH) | 754,638 ₹ 44.75 Cr. | 2,656,075 ₹ 157.51 Cr. | 3.52x |
| HNI2 (>10 LAKH) | 1,509,275 ₹ 89.50 Cr. | 4,145,775 ₹ 245.84 Cr. | 2.75x |
| RETAIL | 5,282,463 ₹ 313.25 Cr. | 8,007,125 ₹ 474.82 Cr. | 1.52x |
| Total | 10,564,926 | 15,078,900 | 1.43x |
*Excluding Anchor
Total No. of Application Approx : ~254275 (1.20 Appwise)
| Appwise Subscription | ||
|---|---|---|
| Category | Total App | App wise |
| HNIBT | 7082.53 2156 (For 1x) | 3.29x |
| HNIAT | 2381.10 4312 (For 1x) | 0.55x |
| RETAIL | 252159.00 211299 (For 1x) | 1.19x |
Disclaimer: The above-mentioned information / data are sourced from the websites of National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) and are subject to change on real time basis. For updated information / data you can visit their respective website. The information / data provided herein above are for information purpose only and provided "AS IS" and "AS AVAILABLE" basis and without warranty, express or implied. We do not guarantee or warrant the accuracy, adequacy or completeness of the information received through the said websites. “We” hold not responsibility of any kind as regard to any discrepancies, errors, omissions, losses or damages. “We” including its affiliates and any of its officers, directors, personnel and employees, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of information / data received through the said websites. The recipient alone shall be fully responsible / are liable for any decision taken on the basis of such information / data. All recipients should before acting upon the said information make their own investigation, seek appropriate professional advice.
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.
The company operates six manufacturing facilities with a combined production capacity of 50,000?MT, specializing in minerals such as calcium, iron, magnesium, zinc, potassium, and sodium
The company supplies more than 200 products to a diverse customer base across pharma, food, and nutrition sectors
The company has strong R&D capabilities with in-house labs and pilot-scale facilities focused on mineral salts and excipients.
Product Portfolio:
As of December 31, 2024, the company had 704 permanent employees.
Sudeep Pharma Ltd.'s revenue increased by 10% and profit after tax (PAT) rose by 4% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 922.26 | 717.17 | 513.87 | 420.11 |
| Total Income | 130.08 | 511.33 | 465.38 | 438.26 |
| Profit After Tax | 31.27 | 138.69 | 133.15 | 62.32 |
| EBITDA | 48.57 | 199.28 | 187.76 | 98.64 |
| NET Worth | 688.32 | 497.53 | 359.07 | 226.29 |
| Reserves and Surplus | 668.52 | 481.11 | 354.59 | 221.88 |
| Total Borrowing | 135.97 | 135.25 | 75.03 | 82.26 |
| Amount in ? Crore | ||||
The Company Sudeep Pharma IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (? in crores) |
|---|---|---|
| 1 | Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I | 75.81 |
| 2 | General corporate purposes |
Once you create your account, Login to InvestoYard.
Under IPO Section, you will be able to see a list of Ongoing IPOs, where you can click on apply button.
Add quantity of shares to apply – Maximum 3 bids are allowed (For retail category – max amount Rs.2,00,000/-).
Enter your UPI ID and you will receive mandate on your UPI App.
Once you accept the mandate, Application is submitted successful.
How to Apply for IPOs on InvestoYard
Step 01 : Once you create your account, Login to InvestoYard.
Step 02 : Under IPO Section, you will be able to see a list of Ongoing IPOs, where you can click on apply button.
Step 03 : Add quantity of shares to apply – Maximum 3 bids are allowed (For retail category – max amount Rs.2,00,000/-).
Step 04 : Enter your UPI ID and you will receive mandate on your UPI App.
Step 05 : Once you accept the mandate, Application is submitted successful.
